Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

304 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate and compare overall patient comfort profile between the Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast media (LOCM), iopamidol 370 mg I/mL in patients undergoing Contrast-Enhanced Computed Tomographic (CECT) imaging of the abdomen/pelvis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Chest CT Using Low-concentration Iodine Contrast Media

NCT05967117

Pulmonary Disease

RECRUITING PHASE4

Study on Sex-specific, Individualized Dose Calculation of Contrast Agent in CT Examinations

NCT06965790

CT Scans Contrast Media Gender +1 more

RECRUITING NA

Comparison of Contrast Agents During CT Angiography

NCT01534975

Contrast Enhancement on Cardiac CT

COMPLETED NA

Customized Contrast Media Dose Clinical Trial

NCT02433665

CT of the Abdomen and Pelvis With Contrast Material

TERMINATED NA

A Non-interventional Study to Observe the Computed Tomographic Angiography Image Quality With Different Contrast Media Injection Protocols Under Different Computed Tomography Machines Parameters Setting

NCT02840903

Angiography Multidetector Computed Tomography

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patient Comfort and Safety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1-Iodixanol

Group Type OTHER

Iodixanol

Intervention Type DRUG

Iodixanol 320 mg I/mL as a single iv. administration.

Arm 2-Iopamidol

Group Type ACTIVE_COMPARATOR

Iopamidol

Intervention Type DRUG

Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Iodixanol

Iodixanol 320 mg I/mL as a single iv. administration.

Intervention Type DRUG

Iopamidol

Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Visipaque Isovue

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject is over 18 years old.
* Subjects are referred to undergo a CECT imaging of the abdomen/pelvis as part of their routine clinical care.

Exclusion Criteria

* The subject has known allergies to iodine or any prior history of adverse reaction to iodinated CM.
* The subject received another administration of CM within 24 hours prior to baseline or is scheduled to receive one within the 24 hour follow-up period.
* The subject is pregnant.
* The subject is taking metformin (e.g., Glucophage®) but is not willing or unable to discontinue at the time of the study procedure.
* The subject manifests thyrotoxicosis or is on dialysis.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No